Two new sets of thiazolopyrimidines IIa-h, IVa-d were designed, synthesized, and screened for their anticancer activity against MCF-7 breast cancer adenocarcinoma, HCT116 colorectal cancer, and HepG2 hepatic cancer.
The safety of the newly synthesized compounds was tested using normal cells (BJ).
Compounds IIa, IId, and IVa showed exceptional cytotoxic activity against both MCF-7 and HepG2, with IC
